Search Results - "Illarramendi, J. J."

Polymorphisms of the Repeated Sequences in the Enhancer Region of the Thymidylate Synthase Gene Promoter May Predict Downstaging After Preoperative Chemoradiation in Rectal Cancer by VILLAFRANCA, Elena, OKRUZHNOV, Yury, ANGELETTI, Silvia, BRUGAROLAS, Antonio, DOMINGUEZ, Miguel A, GARCIA-FONCILLAS, Jesus, AZINOVIC, Ignacio, MARTINEZ, Enrique, ILLARRAMENDI, Jose J, ARIAS, Fernando, MARTINEZ MONGE, Rafael, SALGADO, Esteban

“…Thymidylate synthase (TS) is an important target enzyme for the fluoropyrimidines. TS gene promoter possesses regulatory tandemly repeated (TR) sequences that…”
Get full text

Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study by Arraras, J. I., Illarramendi, J. J., Manterola, A., Asin, G., Salgado, E., Arrondo, P., Dominguez, M. A., Arrazubi, V., Martinez, E., Viudez, A., de la Cruz, S., Vera, R.

“…Purpose In this paper we study the quality of life (QoL) of elderly breast cancer patients receiving endocrine treatment (ET). More QoL data on elderly…”
Get full text

Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice by Blancas, I., Fontanillas, M., Conde, V., Lao, J., Martínez, E., Sotelo, M. J., Jaen, A., Bayo, J. L., Carabantes, F., Illarramendi, J. J., Gordon, M. M., Cruz, J., García-Palomo, A., Mendiola, C., Pérez-Ruiz, E., Bofill, J. S., Baena-Cañada, J. M., Jáñez, N. M., Esquerdo, G., Ruiz-Borrego, M.

“…Introduction This study aimed to describe the efficacy of fulvestrant 500 mg in postmenopausal women with estrogen receptor (ER)-positive advanced/metastatic…”
Get full text

Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice by Blancas, I., Fontanillas, M., Conde, V., Lao, J., Martínez, E., Sotelo, M. J., Jaen, A., Bayo, J. L., Carabantes, F., Illarramendi, J. J., Gordon, M. M., Cruz, J., García-Palomo, A., Mendiola, C., Pérez-Ruiz, E., Bofill, J. S., Baena-Cañada, J. M., Jáñez, N. M., Esquerdo, G., Ruiz-Borrego, M.

“…A sentence under ‘Results’ heading in the Abstract section was published incorrectly. The correct sentence should read as follows:…”
Get full text

Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program by Arias, F, Domínguez, M A, Martínez, E, Illarramendi, J J, Miquelez, S, Pascual, I, Marcos, M

“…Chemoradiotherapy is becoming an alternative to radical cystectomy among patients with muscle invading bladder cancer. We began a prospective study in 1988 to…”
Get more information

Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer by ESPINOSA, E, MORALES, S, JANARIZ, J, DE LA PUENTE, M, CHECA, T, MEL, J. R, GONZALEZ BARON, M, BORREGA, P, CASAS, A, MADRONAL, C, MACHENGS, I, ILLARRAMENDI, J. A, LIZON, J, MORENO, J. A, BELON, J

“…Epirubicin and docetaxel are two of the most active drugs against breast carcinoma. As the achievement of a pathological complete response (pCR) is important…”
Get full text

P1678: ENDOVASCULAR TREATMENT FOR UPPER AND LOWER EXTREMITY DEEP VEIN THROMBOSIS, CASE REPORTS by Casamayor Garcia, A., Aznar Moreno, M. V., Coll Vallier, J., Sola Aparicio, M. E., Gomez Arteta, E., Paloma Mora, M. J., Rodriguez Calvillo, M., Insausti Gorbea, I., Moreno Izco, M. I., Lopez San Martín, M., Monreal Beortegui, R., Anniccherico Sánchez, J., Mugica Muñagorri, I., Gabaldon Limas, D. G., Illarramendi Esteban, J., Breeze, R. J., Ceballos Bolaños, C., Redondo Izal, A. M.

Get full text

Acral keratoses and inverted follicular keratosis presenting Cowden disease by Larumbe, A, Iglesias, M E, Illarramendi, J J, Córdoba, A, Gállego, M

“…Cowden disease is a rare genetic disorder characterized by the presence of multiple hamartomas in the skin, thyroid, breast, nervous system and…”
Get more information

OC-01 Venous thromboembolic events during the first and second waves of Covid-19 in breast cancer patients treated in an outpatient day hospital by Illarramendi, J., Modesto, J.L., Salgado, E., De la Cruz, S., Illarramendi, J.J.

Get full text

Quality of Life Study in Spanish Breast Cancer Patients with the Cortic Questionnaires by J. I. Arraras, E. Pruja, J. J. Illarramendi, M. Tejedor, M. A. Domínguez, J. J. Valerdi

Get full text

Quality of life (QL) in elderly breast cancer survivors. Effects of surgery. Global QL determinants by Arraras, J.I., Illarramendi, J.J., Manterola, A., De la Cruz, S., Asin, G., Salgado, E., Campos, M., Barrado, M., Ibañez, B., Zarandona, U., Rico, M., Dominguez, M.A., Sola, A., Martinez, E.

Get full text

Quality of life in postmenopausal breast cancer patients with localized disease after 5 years of endocrine treatment: A prospective study by Arraras, J.I., Illarramendi, J.J., Manterola, A., Salgado, E., Asin, G., De la Cruz, S., Barrado, M., Campos, M., Ibañez, B., Zarandona, U., Rico, M., Vera, R.

Get full text

Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle by Arias, Fernando, Dueñas, Mayte, Martínez, Enrique, Domínguez, Miguel Angel, Illarramendi, José Juan, Villafranca, Elena, Tejedor, Martín, Molina, Francisco, Meiriño, Rosa, Valerdi, Juan José

“…BACKGROUND Chemoradiotherapy is becoming an alternative to radical cystectomy among patients with bladder carcinoma invading muscle. In 1988, the authors began…”
Get full text

Artifactual hypoglycaemia during treatment with filgrastim (rHu-met-G-CSF) by Illarramendi, J.J., Iruin, A., Mitxelena, I.

Get full text

Neoadjuvant chemotherapy and radiotherapy in locally advanced esophagus carcinoma: long-term results by Valerdi, J J, Tejedor, M, Illarramendi, J J, Dominguez, M A, Arias, F, Martinez, E, Lopez, R

“…A prospective study with neoadjuvant chemotherapy and radiotherapy in patients with locally advanced esophagus carcinoma for evaluating: toxicity, response…”
Get more information

RESULTS OF MMM18 IN A SUBPOPULATION OF STUDENTS IN SPAIN by Rodilla Sala, E., Carreras, B., De Berardinis, B., De La Chica, A., Ruiz, P., Arino, I., Lara, M., Grima, M., Sala, A., Soler, C., Guijarro, P., Illarramendi, J., Pomarés, R., Aspas, M., García, J., Navalón, S., Serra, A., Ruilope, L.M., Molinero, A., Gijón-Conde, T.

Get full text

Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report by Arias, F, Domínguez, M A, Illarramendi, J J, Martínez, E, Tejedor, M, Domínguez, S, Dueñas, M, Villafranca, E, Elcarte, F, Miquéliz, S

“…The feasibility and activity of an intensive chemoradiotherapeutic scheme for patients with locally advanced squamous cell head and neck cancers were tested in…”
Get more information

Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results by Tejedor, M, Valerdi, J J, López, R, Domínguez, M A, Arias, F, Illarramendi, J J, Martínez, E

“…To assess the tolerance, response rate, pattern of failure, and long-term survival of patients with unresectable nonsmall cell lung cancer treated with one…”
Get more information

Cisplatin-based chemotherapy and acute cerebrovascular events by Illarramendi, J J, Gallego, J

Get more information

MERIBEL study: Single-agent eribulin as first-line therapy for taxane-resistant HER2[-] metastatic breast cancer (MBC) patients (pts) by Ortega, V., Lao, J., Garau, I., Afonso, N., Calvo, L., Fernández, Y., Martinez-Garcia, M., Blanco, E., Zamora, P., García, M., Illarramendi, J.J., Rodríguez, C., Aguirre, E., Pérez, J., Castan, J. Cortes, Llombart-Cussac, A.

Get full text